Why Kymera Therapeutics Stock Popped This Week
Yahoo Finance ·
This week was an eventful one for Kymera Therapeutics ( KYMR 7.16% ) . The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch of analyst price target raises. These developments were tempered by news of an insider stock sale. Regardless, by Friday's market close, Kymera had risen by almost 30% over the five trading days, according to data compiled by S&P Global Market Intelligence . Kymera, which specializes in medicines that use a process called targeted protein degradation (TPD), announced Thursday morning that it completed enrollment in a global Phase 2b trial of its leading drug candidate. This is KT-621, which will be tested in a trial to assess its efficacy in treating severe atopic dermatitis, a chronic skin condition. The advancement of any key clinical trial is good news, but what made this one particularly encouraging was that the enrollment for this one was completed far earlier than expected. As a result, the topline data readout for the study is now expected by the end of this year; previously, management was guiding for a mid-2027 target.
DYAX Investor Sentiment
Bullish (Long) 40% · Bearish (Short) 60%
301 participants
Related News
- Meet the Highest-Yielding Stock in the S&P 500. Does Its 10.2% Yield Make It a No-Brainer Buy for Dividend Investors?
- Alphabet (GOOGL) Loses More Gemini Talent To Anthropic And OpenAI
- Weekly Wrap: Bitcoin Nears Two-Year Low
- Why Harmony Gold Mining Stock Plummeted by Almost 12% This Week
- After Issuing Its First Stock Split in 2020, Tesla Took Just 2 Years to Issue Its Second Split. Could a Third Stock Split Come in 2026?
- Why Eli Lilly Stock Jumped to a New All-Time High Today